Preparing for China · patient guide

Diffuse Large B-Cell Lymphoma in China: Understanding Previous Regimens

For a China review of diffuse large B-cell lymphoma, the useful document is a regimen-by-regimen table: drug names, cycles received, dates, response, and why each line stopped. That single record lets a specialist assess relapsed-disease options without re-taking your whole history, and it is different from a first-visit guide.

Go to the practical guidance ↓
AI illustration: A medical professional reviews documents in an office setting.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Why a regimen table beats a rewritten first-visit history

A first-visit guide explains how to organise a whole cancer journey: diagnosis, staging, records, travel, and questions. Your question is narrower. You already have a diagnosis and at least one completed treatment line, and you want a China clinician to understand what was tried and what happened. That is a treatment-history problem, not a general orientation problem.

Lymphoma is not one disease. The National Cancer Institute notes that lymphoma includes Hodgkin and non-Hodgkin types, and that the exact diagnosis matters when discussing treatment. Diffuse large B-cell lymphoma sits within that wider group, so a reviewer needs your specific subtype and biomarker reports, not a generic lymphoma label. The regimen table is the part that turns your file into a usable case.

Think of two documents. The first is your original diagnostic package: pathology, imaging, staging, and molecular or biomarker results. The second is your treatment ledger: what was given, when, how you responded, and why it stopped. A China review needs both, and the ledger is the one to check first, because a diagnostic package without a treatment history cannot show what has already been tried.

What each previous regimen entry should contain

A regimen is not one drug. It is a named combination or single agent, given on a schedule, for a defined number of cycles. If you write only 'chemotherapy' or 'R-CHOP', the reviewer cannot tell whether the schedule was completed, reduced, delayed, or stopped early. Those details change how a later option is judged.

For each line, aim to record the regimen name as written in your records, the individual drugs if listed, the start and end dates, the number of cycles actually received versus planned, the response assessment and how it was measured, and the reason the line ended. The reason matters: completion, progression, toxicity, patient choice, and loss to follow-up are different situations.

Response language is often the hardest part. 'It worked' is not a response category. Look for the scan or clinical note that used a defined term, and quote it. If your records use a local shorthand, include the original wording and let the receiving clinician interpret it rather than translating it yourself.

  • Regimen name exactly as written, plus individual drugs if your record lists them.
  • Start and end dates, and cycles received against cycles planned.
  • Response assessment: the term used, the date, and the test that produced it.
  • Reason the line stopped, in the words of the treating team where possible.
  • Any dose reduction, delay, or substitution, with the stated reason.

Subtype and biomarker reports belong beside the ledger

Two patients with the same regimen history can still be different cases. The pathology report, the cell-of-origin or molecular findings if your laboratory reported them, and any cytogenetic or biomarker results are what let a specialist place your prior treatments in context. Without them, the regimen table describes effort but not the disease it was aimed at.

You do not need to interpret these reports. You need to make them legible. Ask your treating hospital for the full pathology report rather than a summary line, and for any addendum or reflex testing that was performed after the initial diagnosis. If a report exists only in a language other than English, a certified translation of the key sections is usually more useful than a paraphrase.

Where a biomarker result is absent, say so explicitly. 'Not performed' and 'performed but not available' are different gaps, and a reviewer can only ask for the right missing item if the gap is named.

Relapsed-disease questions to ask, not answer, in advance

Once a regimen table exists, the natural next question is what options remain. That question belongs to the treating specialist, and it depends on your prior lines, your response to them, your current disease status, your organ function, and your overall fitness. None of that can be settled by a document alone.

What you can do is prepare the questions so the review is efficient. Ask whether your prior regimens are considered adequate for the options being discussed, whether any prior toxicity limits a future choice, and what additional testing the hospital would want before forming a view. Ask also whether the assessment can be done from records or whether an in-person visit is required.

Be careful with language that assumes access. Cellular therapy, transplantation, and clinical trials each have their own eligibility processes, and a records review does not establish enrolment, access, or availability. If you are interested in one of these routes, ask specifically how that hospital assesses suitability and what it needs from you.

Related treatment reference

A short cover note that makes the file usable

A reviewer opening a large file benefits from one page at the front. Write a dated cover note with your diagnosis as stated, the date of diagnosis, the regimen table, your current status and symptoms, your current medications, and the single question you want answered. Keep it factual and avoid speculation about your own prognosis.

Name your current treating team and whether they know you are seeking an overseas review. This is not a permission slip, but it affects how a second opinion is framed and whether records can be requested smoothly. If you are currently receiving treatment, say so clearly, because any overseas planning must not interrupt it.

Finally, state what you already know is missing. A reviewer who is told 'the 2023 PET report is not yet available' can proceed with the rest and request it later. A reviewer who discovers the gap alone may simply stop.

How to send it, and what happens next

Start with a brief summary rather than a complete archive. An initial enquiry can describe your diagnosis, the number of prior lines, and your main question. The team then identifies what is missing and suggests the relevant next step. This initial review is free and is not a diagnosis or a promise of acceptance.

If a records-based specialist opinion is useful, that can be arranged separately, and it remains optional rather than a prerequisite for every appointment. Hospital consultation fees and any treatment costs are paid to the hospital or provider, while coordination fees are separate. Ask the named hospital what its written plan or quote includes rather than assuming a scope.

The hospital decides suitability. Your job is to make the prior-regimen record clear enough that the decision is made on your actual history, not on a summary that omits the details that matter.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. NCI: Lymphoma Patient Version

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.